Navigation Links
TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
Date:5/14/2009

ons rate implants infections rate De novo 15 0 0.0% 51 0 0.0% Revision 38 0 0.0% 141 5 2.0% Total 53 0 0.0% 192 5 2.0% Other Total infection infection Implant Type implants infections rate implants infections rate De novo 1 0 0.0% 67 0 0.0% Revision 8 0 0.0% 187 5 2.0% Total 9 0 0.0% 254 5 2.0% All Patients w/ greater than or equal to 1 Follow-up & CRMD Infection designation restricted to Generator Pocket Infections Only PM ICD/CRT infection infection Implant Type implants infections rate implants infections rate De novo 15 0 0.0% 51 0 0.0% Revision 38 0 0.0% 141 3 1.2% Total 53 0 0.0% 192 3 1.2% Other Total infection infection Implant Type implants infections rate implants infections rate De novo 1 0 0.0% 67 0 0.0% Revision 8 0 0.0% 187 3 1.2% Total 9 0 0.0% 254 3 1.2% All Patients w/ greater than or equal to 1 Follow-up & CRMD Infection designation restricted to Generator Pocket Infections w/o CRMD infection in prior 6 mos.
'/>"/>
SOURCE TYRX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... October 17, 2014 Investor-Edge has ... (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ... research on these five companies can be accessed at: ... Thursday, October 16, 2014, ended on a mixed note ...
(Date:10/17/2014)... -- UBM Medica US announces that Endocrinology Network , ... who treat patients with type 2 diabetes ... insulin .  Nearly all patients with ... – daily injections of one or more insulin formulations—to ... of pancreatic beta cells. Insulin is a very effective ...
(Date:10/17/2014)...  China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... approval from the China Food and Drug Administration ... complex concentrate ("PCC") at its Shandong Taibang facility. ... production facility for Good Manufacturing Practices ("GMP") compliance ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... Laser,Centers, the largest provider of laser hair removal ... the addition of the VelaShape,cellulite reduction and body ... 30 additional locations before the end of March, ... FDA-approved for both cellulite,reduction and circumferential reduction of ...
... has,received its third $10 million tranche of equity funding ... milestones:,validating the efficacy and safety of its two topical ... influenza vaccine in,ferret studies., The company, a spin-off ... $30 million over the past 18 months from Perseus ...
Cached Medicine Technology:American Laser Center Offers VelaShape Body Shaping and Cellulite Reduction Treatment 2NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones 2
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
(Date:10/20/2014)... 20, 2014 Houston plastic surgeon ... key elements of his innovative True Form Tummy ... surgery residents and faculty at The University of ... too, was once a medical student. Patronella, who is ... cosmetic plastic surgery practices in Texas, The Aesthetic ...
(Date:10/19/2014)... UNITED NATIONS, New York (PRWEB) October 19, 2014 ... the United Nations Population Fund, welcomes news of a ... release of the more than 200 girls who were ... Girls. "These girls have languished in captivity long enough, ... their families, schools and communities," stated Dr. Osotimehin. , ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... who do not have osteoporosis , , FRIDAY, Jan. 18 ... downplay the risks of prescribing bone-strengthening drugs for women ... osteoporosis, a new report claims. , Drugs such as ... fractures of women with osteoporosis, according to the article ...
... funding promotes diabetes care improvement at a community-level, ... throughout the,U.S. in implementing and evaluating models for ... Business Coalition on Health,(NBCH) announced the recipients of ... for NBCH member coalitions -- intended to support ...
... JOSE, Calif., Jan. 18 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... the minimally invasive treatment of venous reflux disease, today,announced ... and,Vice President of Finance and Administration., Mr. Osborne ... in,various senior leadership roles. Mr. Osborne had served as ...
... M.D., distinguished professor of microbiology and immunology and of ... of Yeshiva University, has received the second annual Marshall ... a special ceremony at the medical school. , ... long-time member of the Einstein faculty, Marshall S. Horwitz, ...
... Antipolis, France ---Bridging the unacceptable gap between what is ... the prevention of cardiovascular disease is how Prof Guy ... of the European Society of Cardiology (ESC), summarises the ... , Creating incentives for people to make healthy ...
... to detect surface cancers quickly and painlessly using ... composition has been developed by a QUT PhD ... School of Physical and Chemical Sciences has developed ... diagnose cervical and skin cancers. , Bioimpedance measures ...
Cached Medicine News:Health News:Bone-Strengthening Drugs May Be Overprescribed 2Health News:Bone-Strengthening Drugs May Be Overprescribed 3Health News:National Business Coalition on Health Awards Grants to 14 Coalitions for Diabetes Quality Programs 2Health News:National Business Coalition on Health Awards Grants to 14 Coalitions for Diabetes Quality Programs 3Health News:VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer 2Health News:Einstein honors Dr. Stanley Nathenson with Marshall S. Horwitz Faculty Prize for Research Excellence 2Health News:European Summit on Cardiovascular Disease Prevention 2
Hatsis tying forceps, titanium, long thin tying platforms....
Gills Colibri forceps, very fine pointed tips....
Fine tying forceps, curved tips, wide handle....
Castroviejo tying forceps, tying platforms, straight, 0.3 mm teeth....
Medicine Products: